Clinical effect of different prednisone regimens in the treatment of children with primary nephrotic syndrome and risk factors for recurrence
GENG Hai-Yun, CHEN Chao-Ying, TU Juan, LI Hua-Rong, DU Pei-Wei, XIA Hua, YU Xiao-Ning
Department of Nephrology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing l00020, China (Chen C, Email: chenchaoying484@126.com)
Abstract：Objective To study the clinical effect of full-dose prednisone for 4 or 6 weeks in the treatment of children with primary nephrotic syndrome and its effect on recurrence. Methods A prospective non-randomized controlled clinical trial was performed on 89 children who were hospitalized and diagnosed with incipient primary nephrotic syndrome from December 2017 to May 2019. The children were given prednisone of 2 mg/(kg·day) (maximum 60 mg) for 4 weeks (4-week group) or 6 weeks (6-week group), followed by 2 mg/(kg·day) (maximum 60 mg) every other day for 4 weeks and then a gradual reduction in dose until drug withdrawal. The children were regularly followed up for 1 year. The two groups were compared in terms of the indices including remission maintenance time and recurrence rate. A Cox regression analysis was used to assess the risk factors for recurrence. Results Within 3 months after prednisone treatment, the 4-week group had a significantly higher recurrence rate than the 6-week group (P<0.05). After 1-year of follow-up, there was no significant difference between the two groups in the recurrence rate, remission maintenance time, and recurrence frequency (P>0.05). The risk of recurrence increased in children with an onset age of ≥6 years or increased 24-hour urinary protein (P<0.05). Conclusions For the treatment of incipient primary nephrotic syndrome, full-dose prednisone regimen extended from 4 weeks to 6 weeks can reduce recurrence within 3 months. The children with an onset age of ≥6 years or a high level of urinary protein should be taken seriously in clinical practice, and full-dose prednisone treatment for 6 weeks is recommended to reduce the risk of recurrence.
GENG Hai-Yun,CHEN Chao-Ying,TU Juan et al. Clinical effect of different prednisone regimens in the treatment of children with primary nephrotic syndrome and risk factors for recurrence[J]. CJCP, 2022, 24(8): 853-857.
Abramowicz M, Barnett HL, Edelmann CM, et al. Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children[J]. Lancet, 1970, 1(7654): 959-961. PMID: 4191931. DOI: 10.1016/s0140-6736(70)91093-7.
Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für P?diatrische Nephrologie[J]. Lancet, 1988, 1(8582): 380-383. PMID: 2893190.
6 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis[J]. Kidney Int Suppl (2011), 2012, 2(2): 139-274. DOI: 10.1038/kisup.2012.9.
Norero C, Delucchi A, Lagos E, et al. Initial therapy of primary nephrotic syndrome in children: evaluation in a period of 18 months of two prednisone treatment schedules. Chilean Co-operative Group of Study of Nephrotic Syndrome in Children[J]. Rev Med Chil, 1996, 124(5): 567-572. PMID: 9035508.
Mishra K, Kanwal SK, Sajjan SV, et al. Predictors of poor outcome in children with steroid sensitive nephrotic syndrome[J]. Nefrologia (Engl Ed), 2018, 38(4): 420-424. PMID: 29429831. DOI: 10.1016/j.nefroe.2018.06.009.
Mishra OP, Abhinay A, Mishra RN, et al. Can we predict relapses in children with idiopathic steroid-sensitive nephrotic syndrome?[J]. J Trop Pediatr, 2013, 59(5): 343-349. PMID: 23619602. DOI: 10.1093/tropej/fmt029.
Kikunaga K, Ishikura K, Terano C, et al. High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan (JP-SHINE study)[J]. Clin Exp Nephrol, 2017, 21(4): 651-657. PMID: 27590892. DOI: 10.1007/s10157-016-1319-z.
Webb NJA, Woolley RL, Lambe T, et al. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation[J]. BMJ, 2019, 365: l1800. PMID: 31335316. PMCID: PMC6531851. DOI: 10.1136/bmj.l1800.
Nakanishi K, Iijima K, Ishikura K, et al. Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome[J]. Clin J Am Soc Nephrol, 2013, 8(5): 756-762. PMID: 23371961. PMCID: PMC3641620. DOI: 10.2215/CJN.09010912.
